VYJUVEK (Krystal Biotech) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, And Forecasts, 2020-2025, 2025-2030F, 2035F

(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities include the expansion of gene therapy approvals in dermatology, growing demand for durable rare disease treatments, increased investments in topical gene delivery technologies, and advancements in redosable therapy platforms, all amid rising chronic disease prevalence.

Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The "VYJUVEK Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets's offering.

The Vyjuvek market is experiencing significant growth driven by advancements in gene delivery technologies, emerging topical therapies, and increasing prevalence of chronic conditions. These developments, alongside regulatory support and innovations in redosable therapy platforms, are shaping the future of gene therapies in dermatology, particularly in treating rare genetic disorders.

The ongoing research and breakthroughs in gene delivery vectors have expanded the scope of dermatological gene therapies, with topical solutions showing early success in clinical trials. The focus on rare genetic skin disorders is elevating the demand for innovative solutions, and Vyjuvek, with its functional COL7A1 gene delivery, addresses the critical needs of patients with dystrophic epidermolysis bullosa (DEB).

"Vyjuvek" is pivotal in progressing therapeutic approaches for DEB, promoting wound healing and enhancing skin strength through its topical gel formulated with the aim of achieving sustained collagen production. As chronic diseases become more prevalent, exacerbated by factors such as an aging population and environmental risks, treatments like Vyjuvek offer promising relief by targeting the genetic root causes.

The market for Vyjuvek is witnessing increasing activity, with companies like Krystal Biotech Inc. pioneering new solutions. In May 2023, Krystal Biotech received FDA approval for Vyjuvek, marking it as the first redosable gene therapy for DEB. This approval underscores the therapy's therapeutic impact and suitability for safe, non-invasive administration both clinically and at home.

In a strategic expansion, Krystal Biotech partnered with Swixx BioPharma AG in September 2024 to distribute Vyjuvek in Central and Eastern Europe. This collaboration aims to enhance patient access across the region by leveraging advanced HSV-1 vector-based gene therapy technology.

North America currently leads the Vyjuvek market, with extensive coverage across Asia-Pacific, Europe, and other regions. However, tariff implications are inflating costs related to imported viral vectors and manufacturing inputs, especially in North America and Europe. Despite these challenges, the scenario stimulates local manufacturing investments, fostering resilient supply chains for rare disease treatments.

The Vyjuvek market is defined by sales of the topical gel, valued at factory gate prices. This measure encompasses the complete range of transactions from manufacturers to end customers, omitting resale values along the supply chain. The comprehensive report on the Vyjuvek market provides insights into market size, regional shares, detailed segments, and expansive trend analysis essential for stakeholders to make informed strategic decisions.

Report Scope:

• Market Characteristics: Examines key products, services, and major innovation trends.
• Supply Chain Analysis: Overview of resources and supply chain tiers, including key competitors.
• Trends and Strategies: Insights on digital transformation, automation, sustainability, and AI innovation.
• Regulatory and Investment Landscape: Overview of regulations, policies, and investment flows shaping industry growth.
• Market Size and Forecast: Analysis of historic growth and future projections, influenced by technological and geopolitical factors.
• Total Addressable Market (TAM): Insights into the market potential and strategic growth opportunities.
• Regional Insights: Expanded geographical analysis, including Taiwan and Southeast Asia, reflecting their rising importance in global supply chains.
• Competitive Landscape: Analysis of market dynamics, shares, leading companies, and key financial transactions.
• Company Scoring Matrix: Evaluation of companies based on a mix of market share, innovation, and brand recognition.

Market Segmentation:

• Indication: Epidermolysis Bullosa (EB); Dystrophic Epidermolysis Bullosa (DEB)
• Distribution Channel: Hospital, Retail, and Online Pharmacies
• End User: Adult, Pediatric, Geriatric

Geographic Coverage:

• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN13032026004107003653ID1110857270